

Hatem A Azim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9510449/publications.pdf>

Version: 2024-02-01

57
papers

3,243
citations

201385

27
h-index

174990

52
g-index

57
all docs

57
docs citations

57
times ranked

4600
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer and fertility preservation: international recommendations from an expert meeting. <i>BMC Medicine</i> , 2016, 14, 1.	2.3	521
2	An update on PARP inhibitors moving to the adjuvant setting. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 27-41.	12.5	316
3	Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies. <i>European Journal of Cancer</i> , 2011, 47, 74-83.	1.3	227
4	Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 73-79.	0.8	215
5	Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. <i>Cancer Treatment Reviews</i> , 2016, 49, 65-76.	3.4	167
6	Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. <i>Journal of the National Cancer Institute</i> , 2018, 110, 426-429.	3.0	143
7	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220.	0.9	135
8	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2 Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	0.8	116
9	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. <i>Breast</i> , 2015, 24, 201-207.	0.9	97
10	Tumor <i>PIK3CA</i> Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 981-990.	0.8	95
11	Targeted agents for cancer treatment during pregnancy. <i>Cancer Treatment Reviews</i> , 2015, 41, 301-309.	3.4	84
12	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. <i>Breast</i> , 2018, 42, 41-49.	0.9	75
13	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	0.8	70
14	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	0.8	69
15	Fertility and pregnancy issues in <i>BRCA</i> -mutated breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017, 59, 61-70.	3.4	68
16	Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. <i>European Journal of Cancer</i> , 2015, 51, 1490-1496.	1.3	64
17	Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). <i>Breast Cancer Research and Treatment</i> , 2012, 133, 387-391.	1.1	61
18	Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTTO Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4511.	0.8	60

#	ARTICLE	IF	CITATIONS
19	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014, 21, 545-554.	1.6	58
20	Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-“positive early breast cancer: Analysis from the NeoALTO (BIG 1-06) and ALTO (BIG) Tj ETQp00 0 rgB57Overlock	0.0	0
21	Locoregional treatment of breast cancer during pregnancy. <i>Gynecological Surgery</i> , 2014, 11, 279-284.	0.9	48
22	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	5.8	46
23	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016, 115, 1471-1478.	2.9	45
24	Motherhood after breast cancer: searching for la dolce vita. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 287-298.	1.1	41
25	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTO phase III trial. <i>Breast</i> , 2013, 22, 1060-1065.	0.9	33
26	Final 10-year results of the Breast International Group 2-“98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	1.3	32
27	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	0.9	31
28	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019, 38, 835-844.	1.1	29
29	Clinical utility of genomic signatures in young breast cancer patients: a systematic review. <i>Npj Breast Cancer</i> , 2020, 6, 46.	2.3	29
30	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. <i>Breast</i> , 2015, 24, 290-293.	0.9	27
31	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	3.0	24
32	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 23-32.	1.8	20
33	New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6242-6246.	3.2	15
34	Simultaneous targeting of estrogen receptor and HER2 in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1255-1263.	1.1	14
35	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTO Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	13
36	Estimation of historical control rate for a single arm de-escalation study -“ Application to the POSITIVE trial. <i>Breast</i> , 2020, 53, 1-7.	0.9	13

#	ARTICLE	IF	CITATIONS
37	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	2.3	13
38	Neurofibromatosis type I with breast cancer: not only for women!. <i>Hereditary Cancer in Clinical Practice</i> , 2014, 12, 5.	0.6	12
39	Prognosis of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case-control study. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 489-500.	1.1	10
40	Understanding the factors associated with the surgical management of early breast cancer. <i>Gland Surgery</i> , 2013, 2, 4-6.	0.5	8
41	Fertility preservation in patients with BRCA mutation. <i>Ecancelmedicalscience</i> , 2020, 14, 1033.	0.6	7
42	Breast cancer arising at a young age: Do we need to define a cut-off?. <i>Breast</i> , 2013, 22, 1007-1008.	0.9	6
43	Adjuvant chemotherapy in elderly patients with breast cancer: key challenges. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 661-671.	1.1	6
44	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. <i>JCO Global Oncology</i> , 2022, 8, e2100153.	0.8	6
45	Integrating PARP inhibitors into the management of breast cancer: where are we?. <i>Chinese Clinical Oncology</i> , 2021, 10, 50-50.	0.4	4
46	Response to "Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?". <i>European Journal of Cancer</i> , 2016, 54, 165-166.	1.3	2
47	Response. <i>Journal of the National Cancer Institute</i> , 2018, 110, 919-920.	3.0	2
48	Reply to S. A. Narod et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 4352-4354.	0.8	2
49	POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS596-TPS596.	0.8	2
50	Managing cancer during pregnancy: what evidence do we have?. , 2011, 121, 29-34.		2
51	Potential Therapeutic Targets in Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 215-223.	0.5	1
52	Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100592.	1.0	1
53	Abstract P3-23-03: Use of taxane-containing regimens during pregnancy for the treatment of breast cancer: A systematic review. <i>Cancer Research</i> , 2022, 82, P3-23-03-P3-23-03.	0.4	1
54	What is the role of informed decision-making?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 893-893.	1.1	0

#	ARTICLE	IF	CITATIONS
55	Response. Journal of the National Cancer Institute, 2018, 110, 541-541.	3.0	0
56	Estimation of historical control rate for a single arm de-escalation study: Application to the POSITIVE trial.. Journal of Clinical Oncology, 2018, 36, 552-552.	0.8	0
57	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline <i>BRCA</i> pathogenic variants having a pregnancy after breast cancer. Cancer Research, 2022, 82, PD5-06-PD5-06.	0.4	0